Villora
Secure checkout

Choose your Villora supply.

One capsule a day. Pay once, no subscription, free shipping on 4 and 6 bottles, and 60 days to decide in your own kitchen.

Customer information

Shipping information

Ships from our US warehouse.

We currently ship to the United States only.

Payment

or pay with card

Complete my order

Guaranteed safe & secure checkout
VisaMastercardAmerican ExpressDiscoverPayPalApple Pay
  • One-time purchase, no subscription
  • 60-day money-back guarantee
  • Discreet packaging

Your order

Total
$0
60 days money back guarantee
60 mornings, at our risk. If you don't feel lighter, more regular and more like yourself, email support@tryvillora.com, send the bottles back (even empty) and you get a full refund of your purchase price (return shipping is on you). See our Returns page for how it works, and the guides stay with you.

1 capsule a day · 60-day money-back guarantee · One-time purchase, no subscription

Scientific references 32 sources

References relate to individual ingredients or to general research on the topics discussed on this site; they are not studies of the finished product.

  1. CDC. About Diphyllobothrium. Fish tapeworms up to 30 feet; most infections cause no symptoms. cdc.gov
  2. Fiorenza E.A. et al. (2020). Global Change Biology. Meta-analysis: Anisakis abundance rose 283-fold between 1978 and 2015. doi.org
  3. Carmo J. et al. (2017). BMJ Case Reports. Anisakiasis: a growing cause of abdominal pain. pubmed.ncbi.nlm.nih.gov
  4. CDC DPDx. Diphyllobothriasis. Life cycle and transmission via undercooked fish. cdc.gov
  5. CDC DPDx. Anisakiasis. Symptoms often mistaken for other conditions. cdc.gov
  6. StatPearls (2023). Diphyllobothriasis. Worms 2-15 m long, living 20+ years. ncbi.nlm.nih.gov
  7. Sharma K. et al. (2018). Gastroenterology Research. D. latum case report; the worm absorbs about 80% of dietary B12. pmc.ncbi.nlm.nih.gov
  8. Bao M. et al. (2017). Scientific Reports. Anisakiasis highly underreported; model estimate of about 8,000 cases/year in Spain. nature.com
  9. Mattiucci S. et al. (2013). Emerging Infectious Diseases. Gastric anisakiasis often misdiagnosed in Italy. wwwnc.cdc.gov
  10. Sugiyama H. et al. (2022). Emerging Infectious Diseases. About 19,737 anisakiasis cases/year in Japan. wwwnc.cdc.gov
  11. Mazzucco W. et al. (2018). PLOS ONE. Systematic review, 31,701 participants. Anisakis sensitization reported across many population groups. journals.plos.org
  12. Ahmed M. et al. (2016). Cureus. US anisakidosis case; incidence expected to rise with sushi popularity. pmc.ncbi.nlm.nih.gov
  13. Groudan K. et al. (2023). Case Reports in Gastrointestinal Medicine. Gastric anisakiasis masquerading as reflux. pmc.ncbi.nlm.nih.gov
  14. van der Schoot A. et al. (2022). Am J Clin Nutr. Meta-analysis of RCTs. Psyllium and pectin effective for chronic constipation. pmc.ncbi.nlm.nih.gov
  15. McRorie J.W., McKeown N.M. (2017). J Acad Nutr Diet. Review: gel-forming psyllium softens hard stool and firms loose stool. pubmed.ncbi.nlm.nih.gov
  16. McRorie J.W. et al. (2021). Nutrition Today. Clinical review of psyllium benefits. journals.lww.com
  17. Attaluri A. et al. (2011). Aliment Pharmacol Ther. RCT: prunes outperform psyllium for constipation. pubmed.ncbi.nlm.nih.gov
  18. Chen H.L. et al. (2008). J Am Coll Nutr. Konjac glucomannan improves bowel movement in constipated adults. pubmed.ncbi.nlm.nih.gov
  19. Zhu Y. et al. (2025). Eur J Nutr. Double-blind RCT, 48 athletes with functional constipation. Konjac glucomannan improved gastrointestinal symptoms. pubmed.ncbi.nlm.nih.gov
  20. Sun J. et al. (2020). Asia Pac J Clin Nutr. Randomized trial, 90 adults. Flaxseed improves functional constipation. pubmed.ncbi.nlm.nih.gov
  21. Soltanian N., Janghorbani M. (2019). Clin Nutr ESPEN. RCT in adults with type 2 diabetes. Flaxseed and psyllium vs placebo for constipation. pubmed.ncbi.nlm.nih.gov
  22. Ringel-Kulka T. et al. (2011). J Clin Gastroenterol. L. acidophilus NCFM + B. lactis Bi-07 reduce bloating. pubmed.ncbi.nlm.nih.gov
  23. Martoni C.J. et al. (2020). Nutrients. RCT, 330 adults with IBS. L. acidophilus DDS-1 improves abdominal pain and stool consistency. pmc.ncbi.nlm.nih.gov
  24. U.S. FDA. Prescribing information, semaglutide injection 2.4 mg for chronic weight management. Constipation 24% vs 11% on placebo; delays gastric emptying; postmarketing reports of ileus and severe constipation. accessdata.fda.gov
  25. U.S. FDA (2023). Prescribing information, tirzepatide injection for chronic weight management. Constipation 11% to 17% vs 5% on placebo; delays gastric emptying; caution with oral medications. accessdata.fda.gov
  26. Wilding J.P.H. et al. (2021). N Engl J Med. STEP 1: once-weekly semaglutide 2.4 mg; gastrointestinal events more common than with placebo. pubmed.ncbi.nlm.nih.gov
  27. Jastreboff A.M. et al. (2022). N Engl J Med. SURMOUNT-1: once-weekly tirzepatide in adults with obesity; constipation more frequent than with placebo. pubmed.ncbi.nlm.nih.gov
  28. Gorgojo-Martinez J.J. et al. (2023). J Clin Med 12:145. Expert consensus on gastrointestinal side effects of GLP-1 receptor agonists: fluids, fiber and mobility. doi.org
  29. U.S. Department of Agriculture and HHS. Dietary Guidelines for Americans, 2020-2025. Fiber target of 14 g per 1,000 calories. dietaryguidelines.gov
  30. NIDDK, National Institutes of Health. Definition and facts for constipation. About 16 in 100 adults, and about 33 in 100 adults ages 60 and older, have symptoms of constipation. niddk.nih.gov
  31. NIDDK, National Institutes of Health. Symptoms and causes of constipation: low fiber, not enough liquids, little physical activity, aging, certain medicines; warning signs that need a doctor. niddk.nih.gov
  32. Stanford Health Care. Complications of constipation: hemorrhoids, rectal bleeding, anal fissures, rectal prolapse, fecal impaction. stanfordhealthcare.org

Villora, Daily Gut Support Complex. Gold Angels Agency LLC, 1209 Mountain Road Pl NE Ste R, Albuquerque, NM 87110, USA, is the seller and merchant of record for this product.